Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse

NCT00544999 is registered in ClinicalTrials.gov with Institut de Recherche Clinique sur les Cancers et le Sang as lead sponsor.

NCT NCT00544999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00544999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse
Lead sponsor
Institut de Recherche Clinique sur les Cancers et le Sang
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2007
Completion date
Not reported
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia